mtnbc: tumor mutational burden & pten alterations as molecular correlates
Published 4 years ago • 100 plays • Length 2:03Download video MP4
Download video MP3
Similar videos
-
1:14
the importance of a biomarker-directed approach in triple-negative breast cancer
-
0:51
challenges in the treatment of mtnbc
-
1:07
precision medicine for metastatic triple-negative breast cancer
-
1:33
metaplastic vs. tnbc: comparing long-term outcomes
-
4:11
immunotherapy for tnbc: impassion130 & keynote-355
-
2:30
impassion130: immunotherapy for tnbc
-
2:05
treatment advances in tnbc
-
2:51
tumor mutation burden and neoantigens - bladder cancer video library
-
0:42
can anthracyclines be omitted in tnbc?
-
6:23
unresectable nsclc - tumor mutational burden (tmb), the value in testing
-
6:04
germline brca mutations in tnbc
-
3:00
loss of pten in high grade advanced stage triple negative breast ductal cancers
-
9:32
brca mutation in metastatic tnbc patients
-
1:43
detecting mrd prior to repeat-transurethral resection of bladder tumor in nmibc
-
32:04
educational sessions: "management of special subtypes of tnbc"
-
![analyzing hundreds of markers in a single tumor section [webinar]](https://i.ytimg.com/vi/RAb-SJdrnos/mqdefault.jpg)
33:57
analyzing hundreds of markers in a single tumor section [webinar]
-
0:54
why is io unsucessful in non-tnbc?
-
16:43
2021 west oncology | breast cancer | new advances for metastatic tnbc
-
0:47
breast cancer: treating triple negative breast cancer | upmc